Case Studies
Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making.
Geographic Scope:
Client Situation
The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making.
Trinity’s Solution
Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.…
Read Now
Case Studies
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope:
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC…
Read Now
Case Studies
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
Geographic Scope:
Client Situation:
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity’s Solution
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses,…
Read Now
Case Studies
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope:
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…
Read Now
Briefs
Companies throughout the life sciences industry are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making.
Publication Access Form…
Read Now
Blog
Published July 14, 2020
Executive Summary
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake
Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization
Pharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely to…
Read Now
Briefs
A life science company engaged TGaS Advisors to:
Investigate drivers for gender diversity in VP/SVP commercial roles
Benchmark high-performing companies (in/ex industry) with above-average numbers
of women in executive roles
Benchmark the key competencies and skills of women in executive commercial roles
Complete the form below to view the brief…
Read Now
Blog
Published June 2, 2020
Executive Summary
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited to…
Read Now
Briefs
Trinity explores some of the immediate challenges presented to New Products Planning (also known as Early Commercial Planning or New Product Commercialization) groups.
Publication Access Form…
Read Now
Briefs
While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace.
How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world?
Publication Access Form…
Read Now
